Peptide Bioavailability: How to Read PK and Formulation Claims

Bioavailability describes the rate and extent to which an active ingredient or active moiety is absorbed and becomes available at its site of action. In studies that use blood concentrations as the practical measure, exposure is usually summarized with pharmacokinetic (PK) values such as AUC and Cmax.

Bioavailability belongs to the exact molecule, formulation, route, dose, and study conditions. It is not a property that can be transferred to every product sold under a similar peptide name.

The terms that matter

For an extravascular route, absolute bioavailability is commonly expressed as:

F = (AUC_extravascular / Dose_extravascular) / (AUC_IV / Dose_IV)

That equation is only useful when the comparison is scientifically valid. The studies need a suitable intravenous reference, compatible analyte measurements, adequate sampling, and a design that accounts for dose and clearance. Dividing AUC values pulled from unrelated studies does not produce a reliable bioavailability estimate.

Bioavailability is not efficacy

A PK study can show that a measured analyte reached blood and describe its concentration over time. It cannot, by itself, show that the product:

• improved pain, healing, body composition, cognition, or another clinical outcome;
• reached a particular tissue in an active form;
• produced the same effect as a different route or formulation;
• allowed a proportionally lower dose;
• caused fewer adverse effects; or
• was safe for repeated human use.

The assay also matters. Measuring total radioactivity, a metabolite, or a downstream biomarker is not the same as measuring intact active peptide. A paper should state what the assay detected and how concentrations below the limit of quantification were handled.

Why oral peptide claims are formulation claims

Oral delivery can be difficult because peptides may be degraded in the gastrointestinal tract, cross intestinal or gastric barriers poorly, or show high variability. Formulation strategies can alter those constraints, but evidence for one finished product does not validate an untested capsule, salt, or compounded version.

Approved oral semaglutide is a useful example. The tablet is co-formulated with the absorption enhancer SNAC, and human studies found that food, fasting time, water volume, and tablet erosion affected exposure. FDA labeling also states that the two oral RYBELSUS formulations are not substitutable on a milligram-for-milligram basis. That is evidence of product specificity, not evidence that peptides in general are orally bioavailable.

See the administration-route guide for a broader route comparison and the oral-peptides category for compound-specific evidence summaries.

Claim check: Ac-SDKP is not TB-500

The older version of this page described “Thymosin Beta4 Fragment SDKP” as a modified, orally bioavailable form of TB-500. The molecular identities do not support that claim:

• Full-length thymosin beta-4 contains 43 amino acids.
• FDA defines TB-500 as the N-acetylated seven-amino-acid fragment corresponding to thymosin beta-4 residues 17–23: Ac-LKKTETQ.
• Ac-SDKP is N-acetyl-seryl-aspartyl-lysyl-proline, a distinct four-amino-acid peptide released from the N-terminal region of thymosin beta-4 through enzymatic processing.

Ac-SDKP and TB-500 therefore cannot be treated as synonyms, dose substitutes, or interchangeable evidence. A PK or biological finding for Ac-SDKP does not establish oral bioavailability, efficacy, or safety for TB-500 or full-length thymosin beta-4. FDA’s 2026 review reported that it had not identified human exposure data for drug products containing TB-500.

For identity-specific evidence, use the TB-500 profile.

Claim check: BPC-157 arginate versus acetate

The older page claimed that a BPC-157 arginate salt had more than seven-fold greater oral bioavailability than BPC-157 acetate. No primary study supporting that specific seven-fold arginate-versus-acetate claim was identified in this review.

The published BPC-157 PK paper located for this update studied intravenous and intramuscular administration in rats and beagle dogs. It reported intramuscular absolute bioavailability and rapid metabolism; it did not test oral arginate against oral acetate. Those animal results cannot establish human oral bioavailability or clinical benefit.

FDA’s 2026 evaluation addressed BPC-157 free base and BPC-157 acetate. FDA reported finding no studies that administered BPC-157 to humans through the proposed oral, subcutaneous, nasal, or transdermal routes and no information with which to assess human BPC-157 pharmacokinetics. The document does not identify BPC-157 arginate as a reviewed form.

See the BPC-157 profile for current human-evidence, safety, and regulatory context.

How to audit a bioavailability claim

Before repeating a percentage or comparison, answer each question:

1. What exactly was tested? Record the sequence, salt or counterion, excipients, dosage form, release characteristics, and manufacturer.
2. In whom? Separate cell, animal, healthy-volunteer, and patient evidence. Do not convert an animal percentage into a human estimate.
3. Which route and reference? Absolute bioavailability needs an appropriate intravenous reference; relative bioavailability needs a clearly named comparator.
4. Was exposure dose-normalized? A larger AUC after a larger dose is not automatically better bioavailability.
5. What did the assay measure? Look for intact peptide versus metabolites, total radioactivity, or a pharmacodynamic biomarker.
6. Was sampling adequate? Sparse or truncated sampling can miss Cmax or underestimate AUC.
7. How variable were the results? Check participant count, confidence intervals, coefficient of variation, and values below quantification.
8. What conditions changed exposure? Food, water, fasting, injection site, device, and formulation can matter.
9. Were clinical outcomes measured separately? Exposure is a bridge to outcome research, not a replacement for it.

When a seller gives only a percentage without a study, comparator, species, formulation, assay, or uncertainty estimate, the number is not independently interpretable. Use the purity-testing guide to evaluate identity and assay claims, and review the wiki’s sourcing policy, source directory, and research methodology before relying on a product claim.

References

1. U.S. Food and Drug Administration. Bioavailability Studies Submitted in NDAs or INDs — General Considerations. April 2022.
2. U.S. Food and Drug Administration. Orange Book Preface: bioavailability and bioequivalence definitions.
3. U.S. Food and Drug Administration. RYBELSUS prescribing information. Revised 2025.
4. Bækdal TA, et al. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide. Diabetes Therapy. 2021.
5. Bækdal TA, et al. Relationship between oral semaglutide tablet erosion and pharmacokinetics. Diabetes Therapy. 2021.
6. Drucker DJ. Advances in oral peptide therapeutics. Nature Reviews Drug Discovery. 2020.
7. Kumar N, et al. The anti-inflammatory peptide Ac-SDKP. Pharmacological Research. 2018.
8. Kumar N, et al. Ac-SDKP release from thymosin beta-4 by renal meprin-alpha and prolyl oligopeptidase. American Journal of Physiology. 2016.
9. U.S. Food and Drug Administration. FDA evaluation of TB-500. 2026.
10. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs. Frontiers in Pharmacology. 2022.
11. U.S. Food and Drug Administration. FDA evaluation of BPC-157-related bulk drug substances. 2026.